Insilico Medicine secured inclusion in the Hang Seng Composite Index, granting broader market access and eligibility for Stock Connect—an institutional milestone that increases the company’s visibility and investability amid rising interest in generative AI‑driven drug discovery. Separately, Waiv, the former diagnostics arm of AI biotech Owkin, spun out with $33 million in new funding to commercialize AI‑enabled cancer decision tools. CEO Meriem Sefta said the independent structure lets Waiv pursue clinical and commercial partnerships more aggressively. Together these moves illustrate escalating investor appetite for AI‑first biotech firms and the sector’s bifurcation into public market recognition for established AI players and fresh venture capital for focused spinouts developing clinical diagnostics and decision support.